Temple-Baraitser Syndrome — designated TBS, OMIM #614685, also known as Zimmermann-Laband syndrome type 1 (ZLS1, OMIM #135500) when gingival fibromatosis is present as part of the phenotypic spectrum — a rare autosomal dominant neurodevelopmental syndrome caused by heterozygous gain-of-function variants in KCNH1 (Potassium Channel, Voltage-Gated, Subfamily H, Member 1, chromosome 1q32.2), encoding the EAG1 (ether-à-go-go 1) voltage-gated potassium channel, with fewer than 200 published cases worldwide spanning both Temple-Baraitser and Zimmermann-Laband phenotypic designations — characterized by intellectual disability (moderate to severe in most cases), refractory epilepsy (multiple seizure types often poorly responsive to antiepileptic drugs, present in approximately 70–80% of cases), onychodystrophy (absent, hypoplastic, or dysplastic fingernails and toenails — a highly characteristic and diagnostically useful feature), distinctive facial features (coarse facies, broad nose, full lips, prominent chin), and in some cases gingival fibromatosis (gum overgrowth — the presence of which defines the Zimmermann-Laband designation); the KCNH1/EAG1 channel is widely expressed in the nervous system where it modulates neuronal excitability through voltage-dependent potassium conductance, and gain-of-function variants are predicted to alter the voltage-dependence and kinetics of channel gating in a way that increases potassium current and shifts neuronal excitability; additional gain-of-function variants in KCNK4 can also cause the FHEIG/URMS spectrum (see related guide), while KCNH1 variants define the TBS/ZLS1 spectrum; the epilepsy in TBS is a major clinical burden — seizure onset is typically in infancy or early childhood, seizure types include tonic, clonic, tonic-clonic, myoclonic, and absence seizures, and the epilepsy is characteristically refractory with frequent polypharmacy despite incomplete seizure control; onychodystrophy is present in most TBS cases and ranges from absent nails (anonychia) to dystrophic nails to hypoplastic nails, providing a clinically distinguishing feature visible on physical examination; nail and skin surveillance is warranted given the onychodystrophy; no FDA-approved disease-modifying therapy exists and management is symptomatic, centered on anti-epileptic drug optimization (despite frequently refractory course), nail care and dermatology surveillance, and multi-disciplinary neurodevelopmental support.
Temple-Baraitser Syndrome technology platforms — encompassing the molecular genetics laboratories where exome or genome sequencing identifies gain-of-function KCNH1 variants and distinguishes TBS from ZLS1 based on the presence or absence of gingival fibromatosis, the epilepsy monitoring and seizure tracking platforms where the chronic refractory epilepsy burden of TBS is characterized through EEG, video-EEG, long-term ambulatory monitoring, and anti-epileptic drug management, the nail and dermatology surveillance scheduling platforms where the characteristic onychodystrophy of TBS is followed by dermatology and nail specialist teams, the anti-epileptic drug management portals where the complex polypharmacy required for refractory TBS epilepsy is coordinated with frequent titration appointments and medication level monitoring, and the neurology follow-up scheduling platforms connecting the pediatric neurology, epilepsy, genetics, dermatology, and developmental pediatrics teams — must maintain the availability and performance standards required by the KCNH1 diagnostic urgency, the epilepsy monitoring complexity (frequent medication titration in refractory epilepsy), the nail/dermatology surveillance schedule, and the anti-epileptic drug safety coordination needs of a chronically medicated population. This guide explains why Temple-Baraitser Syndrome tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the diagnostic, epilepsy monitoring, dermatologic, and AED safety needs of modern TBS care.
Why Temple-Baraitser Syndrome Tech Platforms Require Specialized Monitoring Attention
Temple-Baraitser Syndrome management is defined by several clinically urgent platform requirements: the epilepsy monitoring priority — TBS epilepsy is characteristically refractory and requires frequent medication adjustments, EEG monitoring, and real-time seizure burden tracking to guide clinical decisions; platform failures that prevent EEG scheduling, serum AED level monitoring, or seizure diary access directly impair the neurologist's ability to optimize anti-epileptic therapy in a population where medication adjustments are frequent and the consequences of poorly controlled seizures include status epilepticus risk and progressive developmental regression; the nail and dermatology surveillance requirement — onychodystrophy is a defining TBS feature that may be complicated by secondary nail infections, onychomycosis, painful nail remnants requiring removal, and skin abnormalities adjacent to dystrophic nails, requiring scheduled dermatology visits and nail specialist evaluation; the AED safety management imperative — polypharmacy in TBS refractory epilepsy creates drug-drug interaction risks, hepatotoxicity monitoring requirements (valproate), and teratogenicity considerations for female TBS patients of reproductive age, requiring reliable AED management platform availability to coordinate medication monitoring and prescribing decisions; and the molecular diagnostic platform need — KCNH1 variant identification distinguishes TBS/ZLS1 from other neurodevelopmental epilepsy syndromes including those caused by KCNK4 variants, guides genetic counseling, and may enable future KCNH1-targeted therapy enrollment.
Epilepsy monitoring platforms are the highest-priority TBS care technology component. Seizure tracking, EEG scheduling, video-EEG monitoring, and ambulatory EEG must function reliably for a population with refractory, high-burden epilepsy. Monitor epilepsy platforms at 1-minute intervals during clinical hours.
AED management portals coordinate complex polypharmacy in refractory epilepsy. Medication titration records, serum level monitoring, hepatic function monitoring (valproate), and drug-drug interaction checking must be available during the frequent clinical contacts required by refractory TBS epilepsy. Monitor AED management portals at 1-minute intervals during clinical hours.
Dermatology and nail surveillance scheduling platforms coordinate onychodystrophy care. Periodic nail evaluation, dermatology visits, and secondary infection management scheduling must function reliably. Monitor dermatology platforms at 1-minute intervals during clinical hours.
Molecular genetic testing platforms establish the KCNH1 diagnosis. Exome and genome sequencing identifying gain-of-function KCNH1 variants distinguishes TBS from other refractory epilepsy syndromes. Monitor at 1-minute intervals during laboratory hours.
Neurology follow-up scheduling platforms coordinate frequent medication titration appointments. The refractory nature of TBS epilepsy requires frequent neurology visits; scheduling failures create unacceptable gaps in medication management. Monitor at 1-minute intervals during clinical hours.
What to Monitor on a Temple-Baraitser Syndrome Tech Platform
Epilepsy Monitoring — EEG, Video-EEG, and Seizure Tracking
Monitor EEG scheduling and results records (routine EEG scheduling records — baseline EEG for TBS seizure characterization; interval EEG for seizure burden quantification and treatment response monitoring; EEG result transmission records to ordering neurologist; EEG background and ictal pattern characterization records for TBS), video-EEG monitoring records (inpatient and outpatient video-EEG monitoring records for TBS individuals with uncharacterized seizure types or presurgical evaluation; video-EEG capture of seizures enabling seizure type classification — tonic, clonic, tonic-clonic, myoclonic, absence classification affecting AED selection; epilepsy surgery evaluation records where ketogenic diet or surgical options are considered for TBS refractory epilepsy), ambulatory EEG records (home ambulatory EEG monitoring scheduling for TBS individuals to characterize seizure frequency and nocturnal seizure burden between clinic visits; ambulatory EEG download and interpretation records; caregiver seizure diary correlation with ambulatory EEG records), seizure diary and tracking records (electronic seizure diary or app records tracking seizure frequency, seizure type, seizure duration, possible triggers, and post-ictal state for TBS individuals; caregiver seizure log submission and review records; seizure cluster and status epilepticus occurrence records), and status epilepticus management records (TBS individuals at risk for prolonged seizures and status epilepticus; emergency seizure action plan records; rescue medication records — rectal diazepam, intranasal midazolam, buccal midazolam — caregiver training records, prescription and refill management) at 1-minute intervals during clinical hours. Alert immediately — epilepsy monitoring platform failures preventing the seizure diary review for a 9-year-old TBS patient presenting to the neurology clinic for medication adjustment — when the seizure frequency data from the prior 6 weeks that would inform the decision to increase valproate versus add clobazam versus refer for ketogenic diet evaluation is inaccessible due to seizure tracking portal unavailability, preventing the neurologist from making the evidence-based medication titration decision.
Anti-Epileptic Drug Management — Polypharmacy and Safety Monitoring
Monitor AED medication records (TBS medication list records — valproate, clobazam, levetiracetam, lamotrigine, topiramate, rufinamide, or other AED combinations for refractory TBS epilepsy; dose records, titration history, and medication response documentation; medication adherence records and refill management), serum AED level monitoring records (valproate serum level monitoring records — trough and peak levels, therapeutic range documentation, dose adjustment records; clobazam and active metabolite N-desmethylclobazam monitoring records; phenobarbital or phenytoin levels where used; serial level monitoring scheduling coordination), hepatic safety monitoring records (valproate hepatotoxicity monitoring records — LFT panels, ammonia levels, valproate-induced hyperammonemia records; monitoring frequency per valproate prescribing guidelines — biannual LFTs at minimum for chronic valproate; ammonia level monitoring for encephalopathy symptoms), drug-drug interaction records (AED combination interaction documentation for TBS polypharmacy — valproate-lamotrigine pharmacokinetic interaction (valproate inhibits lamotrigine glucuronidation, raising lamotrigine levels); clobazam-valproate interaction records; enzyme-inducing AED interactions with non-AED medications), ketogenic diet records (ketogenic diet initiation and management records for TBS individuals where AED polypharmacy has proven inadequate — dietitian consultation records, ketosis monitoring, diet ratio adjustment records, lipid and growth monitoring), and neurology medication prescribing records (neurologist e-prescribing portal records for TBS AED prescriptions — prescription transmission to pharmacy, prior authorization records for newer AEDs, prescription refill management) at 1-minute intervals during clinical hours. Alert immediately — AED management portal failures preventing the valproate serum level review for a 12-year-old TBS patient on valproate plus lamotrigine — when the serum level data from the recent bloodwork that would inform the neurologist whether to increase the lamotrigine dose (safely, given the current valproate-elevated lamotrigine levels) is inaccessible, preventing the medication adjustment decision at the clinic encounter.
Nail and Dermatology Surveillance — Onychodystrophy Management
Monitor dermatology scheduling and evaluation records (periodic dermatology visit scheduling records for TBS individuals with onychodystrophy — visit frequency determined by severity of nail dystrophy and presence of complications; dermatology evaluation records documenting onychodystrophy severity — anonychia, hypoplasia, or dystrophic nail characterization at each digit; nail bed and periungual tissue condition records), secondary nail infection records (onychomycosis evaluation and treatment records for TBS nail remnants susceptible to fungal colonization — fungal culture records, topical or systemic antifungal treatment records; bacterial paronychia management records; nail removal records for painful dystrophic nail remnants requiring excision), nail care and hygiene records (nail care protocol records for TBS caregivers — protective covering for sensitive nail beds, appropriate footwear for toe onychodystrophy; podiatry referral records for toe nail management), gingival fibromatosis records (gingival overgrowth evaluation records for TBS/ZLS1 individuals with gingival fibromatosis — dentistry and periodontology consultation records; gingival fibromatosis severity scoring; gingivectomy or gingival contouring records for severe gingival overgrowth impairing dentition or hygiene), and skin surveillance records (general skin surveillance records for TBS individuals — any skin comorbidities, AED-induced skin reactions — Stevens-Johnson syndrome risk with lamotrigine requiring slow titration and rash monitoring records) at 1-minute intervals during clinical hours. Alert on sustained failures — dermatology scheduling platform failures preventing the annual onychodystrophy evaluation for a TBS patient with significant hypoplastic nails and a history of recurrent paronychia — when the dermatology visit that would assess for ongoing nail infection and coordinate preventive nail care is deferred.
Neurology Follow-Up — Frequent Medication Titration Appointments
Monitor neurology appointment scheduling records (neurology clinic visit scheduling records for TBS patients — visit frequency determined by seizure control status and AED titration needs; frequent neurology contact for refractory TBS epilepsy, often requiring visits every 4–8 weeks during active medication optimization; neurology telemedicine scheduling records for between-visit medication adjustments), neurodevelopmental follow-up records (developmental pediatrics follow-up scheduling for TBS individuals — cognitive and adaptive function assessment, developmental regression monitoring during seizure clusters, behavioral health review), and epilepsy specialist referral records (tertiary epilepsy center referral records for TBS individuals with inadequately controlled epilepsy — ketogenic diet program, vagus nerve stimulator evaluation, corpus callosotomy or focal surgery evaluation for selected TBS cases where focal seizure onset is documented on video-EEG) at 1-minute intervals during clinical hours. Alert immediately — neurology scheduling platform failures preventing the 6-week follow-up appointment for a 7-year-old TBS patient who had their clobazam dose increased at the last visit — when the follow-up that would assess efficacy and tolerability of the new clobazam dose and determine whether further titration is warranted is deferred by scheduling unavailability, leaving the medication change unreviewed for longer than the clinical protocol specifies.
Molecular Genetic Testing — KCNH1 Identification
Monitor exome sequencing and genome sequencing records (TBS diagnosis by exome or genome sequencing identifying heterozygous gain-of-function KCNH1 variants — de novo in the majority; variant classification records per ACMG criteria; KCNH1 functional annotation records distinguishing gain-of-function from loss-of-function mechanism), TBS versus ZLS1 phenotypic differentiation records (clinical characterization records documenting gingival fibromatosis presence or absence — the phenotypic feature distinguishing ZLS1 from TBS in the KCNH1 gain-of-function spectrum; other KCNH1-variant spectrum conditions records), and genetic counseling records (de novo KCNH1 variant counseling for parents; 50% transmission risk for affected TBS individuals; reproductive counseling; clinical trial eligibility records for KCNH1-targeted therapy development) at 1-minute intervals during laboratory hours. Alert immediately — molecular testing platform failures during the variant analysis for a 3-year-old with refractory epilepsy and onychodystrophy — when the exome data analysis workflow is interrupted before KCNH1 variant calling is completed, delaying the diagnosis that would initiate TBS-specific management and enable communication of the distinctive onychodystrophy monitoring requirement to the care team.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. TBS management coordinates across molecular genetics (KCNH1 identification), pediatric neurology and epilepsy (refractory epilepsy management), EEG and neurophysiology, dermatology (onychodystrophy), dentistry and periodontology (gingival fibromatosis), developmental pediatrics, behavioral health, pharmacy (AED polypharmacy), and ketogenic diet dietetics — authentication failures block every team member required to coordinate the complex TBS care schedule.
SSL Certificates
Monitor SSL certificate expiry across all molecular testing platforms, epilepsy management portals, EEG scheduling systems, AED monitoring platforms, dermatology scheduling portals, and neurology scheduling systems. Certificate errors disrupting AED management portals or seizure tracking systems carry direct patient safety implications for a population with refractory epilepsy and frequent medication titration.
HIPAA and Genomic Privacy Considerations for Temple-Baraitser Syndrome
Temple-Baraitser Syndrome technology platforms handle KCNH1 gain-of-function variant data alongside highly sensitive epilepsy management records including seizure event logs, video-EEG recordings, and AED treatment history. Video-EEG recordings captured during TBS seizure monitoring are particularly sensitive — they capture seizure events in an inpatient or home setting and must be transmitted and stored under HIPAA Security Rule encryption requirements.
TBS individuals with significant intellectual disability require legal guardianship documentation with clear access controls ensuring AED management records, seizure event records, and behavioral health data are accessible only to authorized care team members and legal guardians. For TBS adolescents and adults approaching the age of majority, transition planning for guardianship authorization must be documented in care portals.
Alerting Strategy for Temple-Baraitser Syndrome Tech Platforms
Immediate clinical-hours alerting for epilepsy monitoring platforms: Seizure tracking, EEG scheduling, and seizure action plan access are core TBS management requirements for a population with refractory, high-burden epilepsy.
Immediate clinical-hours alerting for AED management portals: Valproate level monitoring, hepatic safety monitoring, and AED prescribing require reliable platform availability during the frequent clinical contacts driven by refractory TBS epilepsy.
Immediate clinical-hours alerting for neurology scheduling platforms: Frequent medication titration appointments require reliable scheduling to maintain the close clinical follow-up appropriate to active AED optimization.
Immediate clinical-hours alerting for dermatology scheduling platforms: Nail and skin surveillance scheduling for onychodystrophy management.
Immediate laboratory-hours alerting for molecular genetic testing platforms: KCNH1 gain-of-function identification and TBS/ZLS1 distinction.
Sustained-failure alert (10–15 minutes): TBS patient registry, ketogenic diet program coordination, and rare disease community platforms.
30-day advance warning: SSL certificates across all platforms.
Vigilmon's multi-region monitoring confirms TBS platform availability from the geographic regions where comprehensive epilepsy programs, pediatric neurology centers with refractory epilepsy expertise, and dermatology practices with experience in genodermatoses are concentrated.
Status Page for Temple-Baraitser Syndrome Care Team Communication
A real-time status page gives molecular geneticists confirming KCNH1 diagnoses, pediatric neurologists managing refractory TBS epilepsy, EEG technicians scheduling monitoring studies, pharmacists reviewing AED polypharmacy, dermatologists managing onychodystrophy, dentists and periodontologists monitoring gingival fibromatosis, and families coordinating the complex TBS care schedule immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in epilepsy monitoring downtime procedures, AED management platform backup protocols, dermatology scheduling emergency procedures, and neurology clinic communication templates.
Vigilmon Setup for Temple-Baraitser Syndrome Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Seizure tracking and diary platform | 1 min | Slack + PagerDuty (24/7) | | Rescue medication and seizure action plan access | 1 min | Slack + PagerDuty (24/7) | | EEG scheduling (routine, video-EEG, ambulatory) | 1 min | Slack + PagerDuty (clinical hours) | | AED management portal (prescribing, levels, titration) | 1 min | Slack + PagerDuty (clinical hours) | | Valproate serum level and hepatic monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Neurology follow-up scheduling | 1 min | Slack + PagerDuty (clinical hours) | | Exome / genome sequencing (KCNH1 gain-of-function) | 1 min | Slack + PagerDuty (lab hours) | | Genetic counseling platform | 1 min | Slack + PagerDuty (clinical hours) | | Dermatology scheduling (onychodystrophy) | 1 min | Slack + PagerDuty (clinical hours) | | Dentistry / periodontology (gingival fibromatosis) | 2 min | Slack (clinical hours) | | Ketogenic diet program coordination | 2 min | Slack (clinical hours) | | Developmental pediatrics follow-up | 2 min | Slack (clinical hours) | | TBS / KCNH1 patient registry | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure seizure tracking platforms with 24/7 immediate alerting — seizure diary access during after-hours clinical contacts is essential for refractory epilepsy management
- Add rescue medication and seizure action plan platforms with 24/7 alerting
- Configure EEG scheduling platforms with immediate clinical-hours alerting
- Add AED management portals with immediate clinical-hours alerting — polypharmacy monitoring is a continuous TBS management requirement
- Configure valproate and serum AED level monitoring platforms with immediate clinical-hours alerting
- Add neurology follow-up scheduling with immediate clinical-hours alerting
- Configure exome/genome sequencing platforms with immediate laboratory-hours alerting
- Add dermatology scheduling platforms with immediate clinical-hours alerting
- Configure gingival fibromatosis dental/periodontal platforms with sustained-failure alerting
- Add ketogenic diet program coordination platforms with sustained-failure alerting
- Configure TBS patient registry with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all epilepsy monitoring, AED management, dermatology, and molecular testing platforms
- Add the status page URL to epilepsy clinic downtime procedures, AED management platform backup protocols, and rescue medication access emergency procedures
Conclusion
Temple-Baraitser Syndrome technology platforms are embedded in clinical decisions where AED management portal availability during the neurology clinic encounter for an 11-year-old TBS patient on valproate plus lamotrigine plus clobazam — when the seizure diary showing a 40% increase in tonic seizures over the prior 4 weeks and the valproate serum level showing a trough below the therapeutic range should together drive the decision to increase valproate before the next clinic visit, but both the seizure diary access portal and the laboratory result viewer are unavailable during the 45-minute appointment window — leaves the neurologist without the two data elements needed to make an evidence-based medication decision in a child whose refractory epilepsy creates escalating seizure burden whenever titration lags behind the epilepsy's trajectory; where dermatology scheduling platform availability during the scheduled nail care evaluation for a TBS patient with absent fingernails and recurrent paronychia — when the dermatology visit that would assess whether the periungual tissue is harboring a bacterial infection requiring antibiotics or whether the nail remnants are causing persistent pain requiring surgical removal is deferred by scheduling platform unavailability — leaves the nail complication unaddressed and the patient at risk for progressing soft tissue infection in a periungual location where spread to the nail bed and distal phalanx is a recognized complication; and where molecular genetic testing platform availability during the diagnostic evaluation for a 4-year-old with refractory epilepsy, onychodystrophy, and coarse facial features — when the exome sequencing data analysis that would identify the KCNH1 gain-of-function variant and provide the TBS diagnosis is delayed by molecular testing portal unavailability — postpones the diagnosis that would enable the neurologist to search specifically for TBS-associated epilepsy management strategies, trigger dermatology referral for onychodystrophy surveillance, and initiate KCNH1 genetic counseling for the family.
Uptime monitoring gives Temple-Baraitser Syndrome tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to KCNH1 molecular testing laboratories, pediatric epilepsy programs managing refractory TBS seizure burden, EEG departments scheduling monitoring studies, AED management pharmacies coordinating complex polypharmacy, dermatology practices managing onychodystrophy, and compliance auditors that platform operational reliability matches the refractory epilepsy management urgency, AED safety monitoring requirements, and onychodystrophy surveillance complexity of modern TBS care.
Start monitoring your Temple-Baraitser Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #templebaraitser #TBS #zimmermannlaband #ZLS1 #KCNH1 #EAG1 #potassiumchannel #gainoffunction #epilepsy #refractoryepilepsy #onychodystrophy #nails #AED #valproate #EEG #neuroimaging #seizure #ketogenicdiet #neurodevelopmental #HIPAA #healthtech #digitalhealth #uptime #sre